NEJM汇总了10月发表在该刊的三项研究:Retatrutide每周一次治疗阻塞性睡眠呼吸暂停(TRIUMPH-1和-2);小型试验中光遗传学疗法部分恢复视网膜色素变性患者丧失的视力(PIONEER);动态血糖监测可帮助尚未需要胰岛素的2型糖尿病患者(CONNECT)。
Three major October headlines from studies published in NEJM:
1️⃣ Weight-loss drug could help address nighttime sleep disruptions for millions (FOX News) https://nej.md/3UTF6rN
Original Article: Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (TRIUMPH-1 and -2) https://nej.md/4BmAHOI
2️⃣ In small trial, optogenetics restores some vision lost to retinitis pigmentosa (STAT) https://nej.md/4imhuUB
Original Article: Optogenetic Therapy for Restoring Aspects of Visual Function (PIONEER) https://nej.md/4j18UMZ
3️⃣ Glucose Monitors Can Help Type 2 Diabetics Who Don't Yet Need Insulin, Trial Shows (HealthDay) https://nej.md/3WSd6W4
Original Article: Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes (CONNECT) https://nej.md/3TGQNlg
Explore impactful research at http://NEJM.org.
来源:NEJM · x.com